A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation

Brain metastases (BMs) are frequently occurred in lung adenocarcinoma with driver mutation. There is a need to explore multi-discipline treatments and prognostic factors in those patients with most frequent driver mutations: EGFR mutation and ALK fusion. In the retrospective study, different therapi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental metastasis 2020-06, Vol.37 (3), p.391-399
Main Authors: Yang, Haihong, He, Dongyun, Wang, Fengnan, Deng, Qiuhua, Xie, Zixian
Format: Article
Language:English
Subjects:
Adenocarcinoma
Biomedical and Life Sciences
Biomedicine
Brain
Brain cancer
Cancer Research
Enzyme inhibitors
Epidermal growth factor receptors
Gefitinib
Hematology
Kinases
Lung cancer
Lungs
Medical prognosis
Metastases
Metastasis
Mutation
Oncology
Protein-tyrosine kinase
Radiation therapy
Research Paper
Skull
Surgical Oncology
Survival
Tyrosine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Brain metastases (BMs) are frequently occurred in lung adenocarcinoma with driver mutation. There is a need to explore multi-discipline treatments and prognostic factors in those patients with most frequent driver mutations: EGFR mutation and ALK fusion. In the retrospective study, different therapies and prognostic factors were compared between EGFR and ALK -driven lung adenocarcinoma with BMs. 516 patients with EGFR mutation and 76 with ALK fusion were screened for this study, 303 (58.7%) and 34 (44.7%) had BM respectively. In multivariate analyses, the pretreatment factors including delayed BMs and asymptomatic BMs, treatment strategies including the first-generation tyrosine kinase inhibitor (TKI) and cranial radiotherapy (RT) treatment, were associated with much better OS in EGFR mutation patients. Moreover, we found EGFR -mutation patients receiving erlotinib would achieve better survival than those receiving gefitinib ( P  = 0.032). However, BM patients with ALK fusion treated by only the first generation TKI (HR = 0.23, P  = 0.036) or cranial RT (HR = 0.12, P  = 0.003), had better OS. After balancing of baseline characteristics of the two groups, there was no significant difference in the survival between BM patients with EGFR mutation and ALK fusion. And only cranial RT was associated with better survival in those patients (HR = 0.52, P 
ISSN:0262-0898
1573-7276
DOI:10.1007/s10585-020-10026-2